The company has a 50-day moving average price of $17.20 and a 200 day moving average price of $19.02. The brokerage now has $19.00 target price on the stock. As of quarter end Tiaa Cref Investment Management LLC had bought 131,389 shares growing its stake by 715.7%. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.64) by $0.01. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Jefferies raised its rating on Editas Medicine, Inc.to Buy on 10/08/2016 in a reversal from its prior Hold rating.
Several other equities analysts have also issued reports on EDIT. Finally, First American Bank purchased a new stake in shares of Editas Medicine during the second quarter valued at about $251,000. The brokerage set a "hold" rating and a $17.00 price target on the stock. Analysts expect that Editas Medicine will post ($2.84) earnings per share for the current fiscal year. Cann assumed coverage on Editas Medicine in a research note on Monday, July 17th.
(NASDAQ:EDIT) shares saw heavy trading volume with 1,767K shares changing hands in the last trading session. The company's sales was down 8.8% on a YOY basis.
Wall Street analysts are predicting that Editas Medicine Cmn (NASDAQ:EDIT) will report earnings per share of $-0.71 in their quarterly report.
Based on data provided from analysts polled by Thomson Reuters, Editas Medicine, Inc. has a current consensus target price of 35.20.
COPYRIGHT VIOLATION NOTICE: "Editas Medicine, Inc". For the current year the company's revenue estimates are $12.29 Million compared to low analyst estimates of $2.2 Million and high estimates of $29.93 Million according to the prediction of 6 analysts.
On 3/15/2017 Alexandra Glucksmann, COO, sold 1,000 with an average share price of $26.41 per share and the total transaction amounting to $26,410.00. Their average price target spell out an upbeat performance - a 87% and would give EDIT a market capitalization of almost $1.47B. The firm's market capitalization is $803.18 million. Bank of America Corp DE now owns 5,936 shares of the company's stock valued at $133,000 after buying an additional 2,489 shares during the period. Of those insider trades, 39,000 shares of Editas Medicine, Inc. were purchased and 1,000,000 shares were sold.
Editas Medicine (NASDAQ EDIT) opened at 17.14 on Friday. The fund owned 9,101 shares of the company's stock after buying an additional 9,000 shares during the period. Russell Investments Group Ltd. purchased a new stake in Editas Medicine during the fourth quarter worth about $284,000. In terms of relative volume, these shares are trading at 1.7x their normal volume. Hedge funds and other institutional investors own 67.76% of the company's stock. Finally, Fox Run Management L.L.C. acquired a new position in Editas Medicine during the first quarter worth approximately $272,000.
On July 18, 2017 Oppenheimer initiated coverage on EDIT by announcing an initial rating of "Perform". During the same period past year, the firm earned ($0.54) earnings per share. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and global copyright laws. "(NASDAQ:EDIT) PT Set at $27.00 by J P Morgan Chase & Co" was first reported by Stock Observer and is the sole property of of Stock Observer. The shares were purchased at an average cost of $14.07 per share, with a total value of $492,450.00.
Director Kevin Bitterman let go of 1,000,000 shares at an average price of $17.00 on May 22nd.
How Active Are Editas Medicine, Inc. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. After this trade, the executive has an ownership of 4,000 stocks in the company, assessed at roughly $56,600.
Taking a broader look at the analyst consensus, according to 5 analysts Editas Medicine Cmn (NASDAQ:EDIT)'s price will reach at $35.2 during 52 weeks. The disclosure for this bought can be found here. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).